The Value of Amniopatch in Preterm Premature Rupture of Membranes

• Status: Completed
• Trial end date: 2018-03-11
• Target enrollment: 0
• Participant gender: Female

Summary

A randomized controlled trial that involved 100 women diagnosed with PPROM between 24 and 34 weeks of gestational age. Participants were randomized equally into 2 groups. Group I in which amniopatch was done (an amnioinfusion of platelet concentrate followed by fresh frozen plasma in addition to the routine management used in the control group. Group II were treated with routine management including antibiotics and corticosteroids

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Treatments: Ampicillin; Anti-Bacterial Agents; Antibiotics, Antitubercular; BB 1101; Dexamethasone; Dexamethasone acetate; Erythromycin; Erythromycin Estolate; Erythromycin Ethylsuccinate; Erythromycin stearate

Criteria

Inclusion Criteria:

• healthy pregnant women

• gestational age of 24 to 34 weeks (calculated by the sure dates of the last menstrual period and confirmed by early 1st trimesteric ultrasound).

All women carried a normal healthy singleton fetus

Exclusion Criteria:

• established preterm labor at admission

• those with symptoms or signs suggestive of clinical chorioamnionitis.

• women with uncontrolled medical disorder e.g. severe hypertension, uncontrolled diabetes, chronic renal impairment

• women with vaginal bleeding regardless its cause.

• Pregnancies associated with major congenital fetal malformations

• placental insufficiency or anomalies

• anterior position of the placenta

• iatrogenic PPROM